Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Cost of Revenue (2021 - 2025)

Historic Cost of Revenue for Ascendis Pharma A (ASND) over the last 5 years, with Q3 2025 value amounting to $26.1 million.

  • Ascendis Pharma A's Cost of Revenue rose 11244.39% to $26.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $95.1 million, marking a year-over-year increase of 7682.51%. This contributed to the annual value of $49.5 million for FY2024, which is 1134.49% down from last year.
  • Per Ascendis Pharma A's latest filing, its Cost of Revenue stood at $26.1 million for Q3 2025, which was up 11244.39% from $35.6 million recorded in Q2 2025.
  • Ascendis Pharma A's Cost of Revenue's 5-year high stood at $35.6 million during Q2 2025, with a 5-year trough of $1.2 million in Q2 2022.
  • For the 5-year period, Ascendis Pharma A's Cost of Revenue averaged around $12.1 million, with its median value being $10.3 million (2024).
  • In the last 5 years, Ascendis Pharma A's Cost of Revenue surged by 111491.34% in 2023 and then plummeted by 2842.02% in 2024.
  • Ascendis Pharma A's Cost of Revenue (Quarter) stood at $4.0 million in 2021, then rose by 29.38% to $5.2 million in 2022, then soared by 301.47% to $20.9 million in 2023, then fell by 28.42% to $15.0 million in 2024, then soared by 74.4% to $26.1 million in 2025.
  • Its Cost of Revenue stands at $26.1 million for Q3 2025, versus $35.6 million for Q2 2025 and $18.4 million for Q1 2025.